DASHER NEUROSCIENCE HOLDINGS INC.

Area: Government, Academia and Research Institutes

Booth No: M434

Exhibitor Profile

Dasher Neuroscience (7829), a late-clinical-stage biotech on the Taipei Emerging Stock Board, leverages proprietary AI to accelerate therapies for central nervous system (CNS) disorders.

The company is rapidly advancing its flagship candidate, YA-101, for multiple system atrophy (MSA). YA-101 has secured global Orphan Drug Designations (U.S., EU, Japan) and U.S. FDA Fast Track Designation, and is currently in Phase II multi-center trials across the U.S., Japan, and Taiwan.

Beyond MSA, Dasher’s AI-powered pipeline targets Alzheimer’s, schizophrenia, and Parkinson’s disease. Expanding its global footprint, Dasher recently signed an MOU with Norway’s Helse Bergen HF (Haukeland University Hospital). This strategic collaboration integrates Dasher into Europe's prestigious HYDRA Phase III platform trial, significantly accelerating the clinical timeline for its Parkinson’s disease program.